Merck & Co., Inc. Derivative Notional Amount
Merck & Co., Inc. (MRK) had Derivative Notional Amount of $37.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Derivative Instruments and Hedging Activities
us-gaap:DerivativeNotionalAmount · last filed 2026-08-07
- 2026-06-30: Derivative, Notional Amount $37.33B.
- 2026-03-31: Derivative, Notional Amount $42.11B.
- 2025-12-31: Derivative, Notional Amount $40.29B.
- 2025-09-30: Derivative, Notional Amount $42.87B.
| Period end | Derivative, Notional Amount |
|---|---|
| 2026-06-30 | $37.33B 10-Q · filed 2026-08-07 |
| 2026-03-31 | $42.11B 10-Q · filed 2026-05-04 |
| 2025-12-31 | $40.29B 10-Q · filed 2026-08-07 |
| 2025-09-30 | $42.87B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $44.69B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $42.36B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $38.56B 10-K · filed 2026-02-24 |
| 2024-09-30 | $35.31B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $33.10B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $32.22B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $30.55B 10-K · filed 2025-02-25 |
| 2023-09-30 | $29.81B 10-Q · filed 2023-11-03 |
| 2023-06-30 | $29.25B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $30.36B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $28.68B 10-K · filed 2024-02-26 |
| 2022-09-30 | $26.03B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $27.73B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $31.26B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $32.96B 10-K · filed 2023-02-24 |
| 2021-09-30 | $28.46B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $29.43B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $33.99B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $32.78B 10-K · filed 2022-02-25 |
| 2020-09-30 | $27.15B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $23.44B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $27.45B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $30.67B 10-K · filed 2021-02-25 |
| 2019-09-30 | $28.36B 10-Q · filed 2019-11-05 |
| 2018-12-31 | $29.74B 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |